NEW YORK (GenomeWeb) – CollabRx and Cartagenia have teamed up to provide an end-to-end software solution for clinical laboratories that supports genetic testing and reporting, including next-generation sequencing-based tests, in oncology.
Under the terms of their agreement, the partners will integrate Cartagenia's Bench for Oncology software platform with CollabRx's Genetic Variant Annotation service. The combined solution will enable clinical and pathology labs to generate automated workflows that they can use to analyze and report on cancer test results, the partners said. Customers will also have the ability to combine their internal information with CollabRx's medical and scientific knowledge and use it to generate clear and easy-to-understand reports that associate genetic alterations with therapy options.
"CollabRx's scientists and physicians, together with their large network of clinical advisors have thought deeply about curating and annotating medical genomics knowledge to support decision making by physicians who wish to consider a tumor's genetic profile in optimizing a treatment plan for their cancer patients," Steven Van Vooren, one of Cartagenia's scientific founders, said in a statement.
Cartagenia's solution is used by "clinical laboratories that value automation in report generation in combination with tools that allow them to access, review, and validate high-quality knowledge to support the interpretation of results of NGS-based tests in cancer," Thomas Mika, CollabRx's chairman, president, and CEO, said, adding that the partnership will provide a "robust, integrated medical informatics solution to the clinical laboratory market in the US and Europe."
CollabRx and Cartagenia will promote the partnership by cooperating on marketing-related initiatives that will highlight the benefits and advantages of the joint use of each company's products. They will discuss the partnership at this year's Association for Molecular Pathology meeting, which will take place from Nov. 12-15.